At this point, after demonstrating the ability of bevacizumab to reduce the breakdown of the BBB by blocking the overexpression of VEGF and modulating the neuroinflammation induced by TBI, we moved on to the evaluation of the long-term effects of TBI and our treatment on atherosclerosis. The gene discussed is VEGFA; the disease is atherosclerosis.